AMGN

Wells Fargo Upgrades Amgen (AMGN)

On March 13, 2023, Wells Fargo upgraded their outlook for Amgen (NASDAQ:AMGN) from Equal-Weight to Overweight.

Analyst Price Forecast Suggests 15.83% Upside

As of March 13, 2023, the average one-year price target for Amgen is $263.94. The forecasts range from a low of $176.75 to a high of $341.25. The average price target represents an increase of 15.83% from its latest reported closing price of $227.87.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for Amgen is $27,680MM, an increase of 5.16%. The projected annual non-GAAP EPS is $18.93.

Amgen Declares $2.13 Dividend

On March 7, 2023 the company declared a regular quarterly dividend of $2.13 per share ($8.52 annualized). Shareholders of record as of May 18, 2023 will receive the payment on June 8, 2023. Previously, the company paid $2.13 per share.

At the current share price of $227.87 / share, the stock's dividend yield is 3.74%. Looking back five years and taking a sample every week, the average dividend yield has been 2.98%, the lowest has been 2.45%, and the highest has been 3.67%. The standard deviation of yields is 0.28 (n=237).

The current dividend yield is 2.70 standard deviations above the historical average.

Additionally, the company's dividend payout ratio is 0.69. The payout ratio tells us how much of a company's income is paid out in dividends. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend. A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Companies with few growth prospects are expected to pay out most of their income in dividends, which typically means a payout ratio between 0.5 and 1.0. Companies with good growth prospects are expected to retain some earnings in order to invest in those growth prospects, which translates to a payout ratio of zero to 0.5.

The company's 3-Year dividend growth rate is 0.33%, demonstrating that it has increased its dividend over time.

What are Large Shareholders Doing?

AMGN / Amgen, Inc. Shares Held by Institutions

VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 16,218K shares representing 3.04% ownership of the company. In it's prior filing, the firm reported owning 15,956K shares, representing an increase of 1.62%. The firm increased its portfolio allocation in AMGN by 9.38% over the last quarter.

Primecap Management holds 15,292K shares representing 2.86% ownership of the company. In it's prior filing, the firm reported owning 15,565K shares, representing a decrease of 1.78%. The firm decreased its portfolio allocation in AMGN by 99.89% over the last quarter.

VFINX - Vanguard 500 Index Fund Investor Shares holds 12,335K shares representing 2.31% ownership of the company. In it's prior filing, the firm reported owning 12,126K shares, representing an increase of 1.69%. The firm increased its portfolio allocation in AMGN by 9.19% over the last quarter.

Capital Research Global Investors holds 11,918K shares representing 2.23% ownership of the company. In it's prior filing, the firm reported owning 12,605K shares, representing a decrease of 5.77%. The firm increased its portfolio allocation in AMGN by 1.34% over the last quarter.

Geode Capital Management holds 11,376K shares representing 2.13% ownership of the company. In it's prior filing, the firm reported owning 11,201K shares, representing an increase of 1.54%. The firm increased its portfolio allocation in AMGN by 9.41% over the last quarter.

What is the Fund Sentiment?

There are 3720 funds or institutions reporting positions in Amgen. This is an increase of 238 owner(s) or 6.84% in the last quarter. Average portfolio weight of all funds dedicated to AMGN is 0.55%, a decrease of 9.17%. Total shares owned by institutions decreased in the last three months by 0.39% to 450,686K shares. The put/call ratio of AMGN is 0.85, indicating a bullish outlook.

AMGEN Background Information
(This description is provided by the company.)

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.